ArticleCureus2025
Immunotactoid Glomerulopathy in a Patient With HIV and Anti-hepatitis C Virus (HCV) Positivity: A Unique Clinical Entity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotactoid glomerulopathy (ITG) is a rare glomerular disease characterized by organized immunoglobulin deposits forming microtubular structures on electron microscopy. While ITG has been individually associated with HIV and hepatitis C virus (HCV) infections, there are few case reports with concurrent HIV infection and anti-HCV antibody positivity. We report a 57-year-old Hispanic female with HIV infection since 2007 and positive anti-HCV antibodies who presented with nephrotic-range proteinuria (urine protein-to-creatinine ratio: 7,834 mg/gm), hematuria, and hypertension. Renal biopsy revealed enlarged glomeruli with diffuse mesangial expansion, segmental endocapillary proliferation, and characteristic organized microtubular deposits on electron microscopy. Immunofluorescence demonstrated granular staining for IgG (both IgG1 and IgG2 subclasses), kappa and lambda light chains, and C3, confirming polyclonal ITG. Extensive hematologic workup was negative for lymphoproliferative disorders. Given the patient's immunocompromised status, immunosuppressive therapy was avoided. Treatment focused on optimizing antiretroviral therapy, transitioning from oral to long-acting injectable regimens (including lenacapavir), which improved viral suppression and CD4 counts. Proteinuria management included angiotensin-converting enzyme inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors, resulting in significant proteinuria reduction while maintaining preserved renal function (serum creatinine ≤1.0 mg/dL). This is a unique case of ITG in a patient with concurrent HIV infection and anti-HCV seropositivity. Our case demonstrates that polyclonal ITG in immunocompromised patients can be effectively managed without immunosuppression through optimized antiretroviral therapy and nephroprotective agents, including SGLT2 inhibitors. This approach offers a novel therapeutic strategy that avoids the risks of immunosuppression in vulnerable populations while achieving favorable clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.